SCHEMBL5382602

SCHEMBL5382602

COc1ccccc1CSc1nc(Nc2ccc(C)cc2)n[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 11/20 0.54
SMN1; SMN2 Q16637 2/20 0.48
KDM1A O60341 1/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RCOR1 Q9UKL0 1/20 0.44
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
CASP3 P42574 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
CTSB P07858 1/20 0.43
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5385430 0.91 METAP2 (0.66) METAP2SMN1; SMN2KDM1AGAAHSD17B10
SCHEMBL5385333 0.90 METAP2 (0.53) METAP2SMN1; SMN2KDM1AGAAHSD17B10
SCHEMBL5371943 0.88 METAP2 (0.47) METAP2SMN1; SMN2KDM1AGAAHSD17B10
SCHEMBL5372069 0.88 METAP2 (0.56) METAP2SMN1; SMN2KDM1AGAAHSD17B10
SCHEMBL5372035 0.86 METAP2 (0.69) METAP2SMN1; SMN2GAAMAPTMEN1
SCHEMBL5377090 0.86 METAP2 (0.63) METAP2SMN1; SMN2GAAMAPTMEN1
SCHEMBL5396958 0.85 METAP2 (0.49) METAP2SMN1; SMN2KDM1AGAAHSD17B10
SCHEMBL5396948 0.85 METAP2 (0.55) METAP2SMN1; SMN2KDM1AGAAHSD17B10
SCHEMBL5372326 0.84 METAP2 (0.50) METAP2SMN1; SMN2KDM1AGAAHSD17B10
SCHEMBL5371983 0.84 METAP2 (0.66) METAP2SMN1; SMN2KDM1AGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304082-B2 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-04 US disclosed
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use METAP2, METAP1, DNPEP METAP2 1/4885SMN1; SMN2 4773/4885KDM1A 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.